손발톱진균증 치료 시장 보고서 : 질환 유형별, 치료 유형별, 약물 종류별, 유통 채널별, 지역별(2026-2034년)

The global onychomycosis treatment market size reached USD 3.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.15% during 2026-2034. North America exhibits a clear dominance in the market, owing to the improvements in the healthcare infrastructure. The rising prevalence of this fungal infection among adults and millennials due to the increased exposure to public swimming pools and the use of tight, contaminated, or soiled clothes, shoes, socks, etc., is primarily driving the market.

MARKET SIZE & FORECASTS:

• Onychomycosis treatment market was valued at USD 3.8 Billion in 2025.
• The market is projected to reach USD 5.5 Billion by 2034, at a CAGR of 4.15% from 2026-2034.

DOMINANT SEGMENTS:

• Disease Type: Distal subungual onychomycosis currently exhibits a clear dominance in the market, characterized by the invasion of the nail bed and underside of the nail plate, leading to discoloration, thickening, and detachment of the nail.
• Treatment Type: Drug treatment holds the biggest market share as it involves oral and topical antifungal medications, each with distinct examples of efficacy in treating the condition.
• Distribution Channel: Retail pharmacies account for the majority of the total market share, reflecting their pivotal role in the distribution and accessibility of antifungal medications.
• Region: North America leads the market, owing to the elevating usage of topical nail lacquers and ointments to maintain nail hygiene.

KEY PLAYERS:

• The leading companies in the market include Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Galderma Holding S.A., GSK plc., Kaken Pharmaceutical Co., Ltd., Lumenis Be Ltd, Moberg Pharma AB (publ), Novartis AG, Pfizer Inc., TheOTCLab B.V., Xian Janssen Pharmaceutical Ltd., etc.

KEY DRIVERS OF MARKET GROWTH:

• Growth in Onychomycosis Prevalence: Increased cases of onychomycosis, spurred by age groups, diabetes, and other health ailments, are driving demand for successful treatments.
• Innovation in Treatment: Continued research and innovation are bringing emerging antifungal treatments, such as oral drugs, topical medications, and laser treatments, which enhance treatment efficiency and patient outcomes.
• Rising Awareness and Diagnosis Levels: Greater awareness about onychomycosis and improved diagnostics are causing earlier diagnosis and treatment, thus opening up the market. Better Accessibility to Treatment: The increasing availability of over-the-counter treatment and more specialized clinics are increasing the accessibility to treatment to a larger patient base.
• Increasing Aesthetic Issues: Increasing issues related to the look of nails are leading people to opt for treatment, especially in cosmetic and aesthetic settings, which is fueling the growth of the market.

FUTURE OUTLOOK:

• Strong Growth Outlook: The market for the treatment of onychomycosis is witnessing prolonged growth, driven by ongoing innovation, heightened awareness, and wider accessibility to treatment modalities.
• Market Evolution: The industry is shifting in favor of personalized therapies that are specific to the patient's profile, with the end goal of bringing more efficient and targeted treatments to onychomycosis.

Onychomycosis treatment market is witnessing strong growth and change as the world's healthcare dynamics evolve to reflect the increased incidence of fungal nail infections. Currently, the regulatory environment is in the process of change as governments and healthcare agencies across the globe are recognizing the increasing burden of onychomycosis. Organizations like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are also rapidly approving new antifungal therapies, driving additional innovation in the industry. Moreover, regulatory agencies are striving to make treatments safe and effective, which is contributing toward the trust of patients in existing treatments and toward more widespread use of new therapy.

ONYCHOMYCOSIS TREATMENT MARKET TRENDS:

Technological Advances in Treatment Techniques

Technological progresses in treatment techniques are having a strong influence on the onychomycosis treatment sector. Ongoing research and development (R&D) are fueling new antifungal drugs, laser therapy, and more sophisticated diagnostics. Oral antifungal drugs like terbinafine and itraconazole are being improved to increase their efficacy, while topical drugs are adapting to provide more accessible and less painful alternatives. Laser therapy, which focuses light energy to kill fungal infections, is becoming increasingly popular because it provides precise and limited side effects. In addition, novel diagnostic technologies that facilitate more precise and quicker identification are improving treatment outcomes by enabling earlier treatment. Such advances are making treatments safer, more effective, and more convenient for patients to receive. Consequently, the onychomycosis treatment market is growing as new technology improves the overall experience of treatment. In 2024, Eisai Company, Limited declared that the company signed a licensing agreement concerning the development and commercialization rights for the antifungal drug fosravuconazole in the Asia/Oceania region* with Sato Pharmaceutical Co., Ltd. Under this agreement, Eisai grants Sato Pharma exclusive rights to the intellectual property of fosravuconazole in the specified countries/regions.

Increased Awareness about Onychomycosis

Increased awareness about onychomycosis is a major driver for the treatment market. Rising efforts to make the population aware of the cause, symptoms, and risks associated with fungal nail infections are witnessing. Health institutions, dermatologists, and public health initiatives are disseminating information on how treatment and prevention of onychomycosis can be achieved. Consequently, more people are becoming aware of the condition and going for early treatment. This is particularly relevant in areas where the stigma attached to nail infections has previously made people reluctant to go for medical care. As information becomes more readily available, patients are increasingly taking control of the problem, resulting in increased diagnosis and treatment demand. The heightened awareness is building a more educated patient base, which is driving market expansion as people seek solutions to enhance their quality of life. In 2024, CDC and WHO conducted Fungal Disease Awareness Week 2024, where experts shared information in diagnostics and susceptibility testing. These initiatives were also responsible for increasing the awareness about fungal diseases like onychomycosis.

Aging Population and Demographic Changes

The growing population of older individuals is playing a big role in the expansion of the market size. According to the predictions of WHO, the number of individuals aged 60 and over will increase 1.4 billion by 2030. As individuals grow older, immune systems are weakened, and circulation tends to decrease, both of which heighten the risk of fungal nail infections. In addition, older persons tend to have more comorbid conditions like diabetes or peripheral vascular disease, further increasing their risk. The shift in demographics to an aging population, specifically within developed areas, is driving the need for treatments specific to this population. Pharmaceutical organizations are emphasizing developing therapy that is safe and effective for the elderly patient, many of whom will have contraindications or sensitivities to certain drugs. Thus, the market is observing a rise in demand for treatments that are appropriate for the aging population, including those with minimal side effects and simpler administration techniques, for example, topical antifungal solutions or laser treatments.

ONYCHOMYCOSIS TREATMENT MARKET GROWTH DRIVERS:

Growing Incidence of Onychomycosis

The increasing prevalence of onychomycosis is impelling the market growth. With an aging global population, the rates of fungal nail infection are rising, especially in older adults. Such individuals tend to have compromised blood circulation, weakened immune systems, and altered nail structure, all of which predispose them to onychomycosis. Also, with increasing prevalence of chronic diseases like diabetes, the risk of fungal infection of the nails continues to rise. With more individuals suffering from onychomycosis, there has been a growing need for treatment of the condition. Healthcare professionals are more actively diagnosing and treating the condition early, which is part of the reasons for increasing treatment rates. Consequently, dermatologists and pharmaceutical firms are concentrating on creating new and better treatments for these section of patients.

Growing Preference for Non-Invasive Treatments

The growing preference for non-invasive treatments is transforming the market for onychomycosis treatment. Patients are looking for alternatives to oral drugs, which can have side effects or cause extended treatment regimens. Topical medications, like antifungal gels and lacquers, are increasingly popular since they are convenient to use and may be purchased over the counter. These medications are viewed as less risky and more convenient than oral drugs. In addition, non-surgical methods such as laser treatment are also gaining popularity within the clinic because they can cure the infection without drugs and with minimal recovery time. Non-invasive treatments are especially attractive to patients who are worried about the possible side effects or systemic effects of oral antifungal therapy.

Increasing Access to Treatment

Increasing access to onychomycosis treatment is one of the drivers of the market. With improving healthcare systems around the world, treatment options are readily available to patients, especially in remote or underprivileged regions. The growing availability of antifungal medication over the counter is a major aspect of how access is becoming greater. Patients no longer require a prescription for less severe cases of onychomycosis, making treatment easier and less expensive. Also, the rise of online pharmacies and e-commerce sites is giving customers the option to buy medicines from the convenience of their homes, enhancing the accessibility of medication in areas where there are limited pharmacies or healthcare centers. Moreover, the increase in number of specialist dermatology clinics is enhancing access to expert care so that patients are provided with the most suitable treatment for their ailment. This increased availability is driving more individuals to pursue care.

GLOBAL ONYCHOMYCOSIS TREATMENT INDUSTRY SEGMENTATION:

Breakup by Disease Type:

• Distal Subungual Onychomycosis
• Proximal Subungual Onychomycosis
• White Superficial Onychomycosis
• Candidal Onychomycosis
• Others

Distal subungual onychomycosis currently exhibits a clear dominance in the market

Distal subungual onychomycosis (DSO) is the most common form of fungal nail infection, characterized by the invasion of the nail bed and underside of the nail plate, leading to discoloration, thickening, and detachment of the nail. Recent advancements in the treatment of DSO have seen the launch of several innovative therapies aimed at improving patient outcomes. Topical antifungal solutions with enhanced nail penetration capabilities, such as efinaconazole and tavaborole, have been introduced, providing effective alternatives to oral medications. Additionally, the advent of laser treatments specifically designed for DSO has gained traction, offering a non-invasive and painless option that targets the fungal pathogens directly. New combination therapies, integrating both topical and oral agents, have also been launched to tackle the persistent nature of DSO by employing a multifaceted approach. In November 2023, Blueberry Therapeutics Limited, one of the pharmaceutical companies focused on developing innovative nanomedicines to treat dermatological conditions, introduced BB2603, a novel topical terbinafine antifungal product to treat distal subungual onychomycosis.

Breakup by Treatment Type:

• Laser Therapy
• Photodynamic Therapy
• Drug Treatment

Currently, drug treatment holds the largest market share

Drug treatment for onychomycosis mainly involves oral and topical antifungal medications, each with distinct examples of efficacy in treating the condition. Oral antifungals like terbinafine (Lamisil) and itraconazole are commonly prescribed due to their ability to reach the nail bed through the bloodstream, effectively targeting the fungal infection from within. On the other hand, topical treatments, such as ciclopirox and efinaconazole, offer non-invasive options that are applied directly to the affected nail. Ciclopirox is a nail lacquer that is applied daily and gradually penetrates the nail to eradicate the fungus. For example, in July 2022, Zydus Lifesciences received approval from the U.S. Food and Drug Administration (USFDA) to market an antifungal efinaconazole topical solution for onychomycosis.

Breakup by Drug Class:

• Allylamine
• Azole
• Griseofulvin
• Others

Allylamines, such as terbinafine, are prominently featured due to their high efficacy and relatively short treatment duration, making them a preferred choice for both patients and healthcare providers. Azoles, including itraconazole and fluconazole, are also thoroughly examined, highlighting their broad-spectrum antifungal activity and flexibility in dosing regimens, which cater to patients requiring alternative treatment options. Griseofulvin, an older antifungal, is analyzed for its continued use in cases where other treatments are contraindicated. The report further explores other emerging drug classes and novel antifungal agents that are being developed to address the limitations of existing therapies, which is propelling the onychomycosis treatment market share. This analysis not only informs about the market dynamics but also aids in understanding the evolving preferences and trends in antifungal treatments.

Breakup by Distribution Channel:

• Hospitals and Clinics
• Online Stores
• Retail Pharmacies
• Others

Retail pharmacies account for the majority of the total market share

Retail pharmacies represented the largest segment in the onychomycosis treatment market, reflecting their pivotal role in the distribution and accessibility of antifungal medications. This dominance is attributed to the convenience and widespread availability of retail pharmacies, making it easier for patients to obtain both prescription and over-the-counter treatments. For example, widely used oral antifungals like terbinafine (Lamisil) and itraconazole (Sporanox) are commonly dispensed through retail pharmacies, allowing for prompt initiation of treatment following a diagnosis. Additionally, popular, topical solutions such as ciclopirox (Penlac) and efinaconazole (Jublia) are readily accessible at these outlets, providing non-invasive treatment options for patients. The extensive reach of retail pharmacies, often supplemented by in-store pharmacist consultations, supports patient adherence to treatment regimens, thereby enhancing the effectiveness of therapy. This segment's growth is further bolstered by the increasing availability of online pharmacy services, which offer added convenience and discreet purchasing options, catering to the evolving preferences of consumers seeking onychomycosis treatments.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America currently dominates the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The expanding geriatric population is primarily driving the market. The Census Bureau estimated that more than 55 million individuals in the U.S. are aged 65 years or older, out of which one-fourth live in one of three states, namely Florida, California, and Texas. Besides this, the rising number of regulatory approvals is also acting as another significant growth-inducing factor. For example, in April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) received tentative approval from the U.S. Food & Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for the treatment of onychomycosis in the toenail. Similarly, in February 2021, Lupin Limited received the U.S. Food and Drug Administration's approval for its tavaborole topical solution for onychomycosis.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Bausch Health Companies Inc.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Galderma Holding S.A.
• GSK plc.
• Kaken Pharmaceutical Co., Ltd.
• Lumenis Be Ltd
• Moberg Pharma AB (publ)
• Novartis AG
• Pfizer Inc.
• TheOTCLab B.V.
• Xian Janssen Pharmaceutical Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global onychomycosis treatment market in 2025?

2. What is the expected growth rate of the global onychomycosis treatment market during 2026-2034?

3. What are the key factors driving the global onychomycosis treatment market?

4. What has been the impact of COVID-19 on the global onychomycosis treatment market?

5. What is the breakup of the global onychomycosis treatment market based on the disease type?

6. What is the breakup of the global onychomycosis treatment market based on the treatment type?

7. What is the breakup of the global onychomycosis treatment market based on the distribution channel?

8. What are the key regions in the global onychomycosis treatment market?

9. Who are the key players/companies in the global onychomycosis treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Onychomycosis Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Disease Type

• 6.1 Distal Subungual Onychomycosis
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Proximal Subungual Onychomycosis
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 White Superficial Onychomycosis
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Candidal Onychomycosis
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Treatment Type

• 7.1 Laser Therapy
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Photodynamic Therapy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Drug Treatment
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Drug Class

• 8.1 Allylamine
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Azole
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Griseofulvin
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospitals and Clinics
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Online Stores
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Retail Pharmacies
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Bausch Health Companies Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Cipla Limited
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Dr. Reddy's Laboratories Ltd.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Galderma Holding S.A.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 GSK plc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Kaken Pharmaceutical Co., Ltd.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
  • 15.3.7 Lumenis Be Ltd
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 SWOT Analysis
  • 15.3.8 Moberg Pharma AB (publ)
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
  • 15.3.9 Novartis AG
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Pfizer Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 TheOTCLab B.V.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
  • 15.3.12 Xian Janssen Pharmaceutical Ltd.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis